Have a feature idea you'd love to see implemented?
Let us know!
INCY Incyte Corp
Price (delayed)
$65.19
Market cap
$12.56B
P/E Ratio
171.55
Dividend/share
N/A
EPS
$0.38
Enterprise value
$11.6B
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,
Highlights
INCY's gross profit is up by 10% year-on-year and by 2.3% since the previous quarter
Incyte's revenue has increased by 10% YoY and by 2.4% from the previous quarter
INCY's P/E is 199% above its last 4 quarters average of 57.7
INCY's EPS has shrunk by 89% QoQ and by 77% YoY
Key stats
What are the main financial stats of INCY
Market
Valuations
Earnings
Shares outstanding
192.6M
Market cap
$12.56B
Enterprise value
$11.6B
Price to earnings (P/E)
171.55
Price to book (P/B)
4.88
Price to sales (P/S)
3.69
EV/EBIT
32.8
EV/EBITDA
26.31
EV/Sales
3.01
Revenue
$3.86B
EBIT
$353.65M
EBITDA
$440.8M
Free cash flow
-$138.12M
Per share
Balance sheet
Liquidity
EPS
$0.38
Free cash flow per share
-$0.63
Book value per share
$13.35
Revenue per share
$17.68
TBVPS
$20.13
Total assets
$4.66B
Total liabilities
$1.66B
Debt
$32.62M
Equity
$3B
Working capital
$1.23B
Debt to equity
0.01
Current ratio
1.92
Quick ratio
1.69
Net debt/EBITDA
-2.17
Margins
Efficiency
Dividend
EBITDA margin
11.4%
Gross margin
93.1%
Net margin
2.5%
Operating margin
0.4%
Return on assets
1.6%
Return on equity
2.1%
Return on invested capital
17.4%
Return on capital employed
10.6%
Return on sales
9.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INCY stock price
How has the Incyte stock price performed over time
Intraday
-0.61%
1 week
-1.48%
1 month
1.67%
1 year
18.31%
YTD
3.82%
QTD
-1.38%
Financial performance
How have Incyte's revenue and profit performed over time
Revenue
$3.86B
Gross profit
$3.59B
Operating income
$15.74M
Net income
$97.3M
Gross margin
93.1%
Net margin
2.5%
Incyte's operating income has plunged by 98% from the previous quarter and by 96% YoY
INCY's operating margin has dropped by 98% since the previous quarter and by 97% year-on-year
The net margin has dropped by 87% since the previous quarter and by 76% year-on-year
INCY's net income has dropped by 87% since the previous quarter and by 73% year-on-year
Growth
What is Incyte's growth rate over time
Valuation
What is Incyte stock price valuation
P/E
171.55
P/B
4.88
P/S
3.69
EV/EBIT
32.8
EV/EBITDA
26.31
EV/Sales
3.01
INCY's P/E is 199% above its last 4 quarters average of 57.7
INCY's EPS has shrunk by 89% QoQ and by 77% YoY
The stock's price to book (P/B) is 58% more than its last 4 quarters average of 3.1 but 3.7% less than its 5-year quarterly average of 5.1
INCY's equity is down by 44% since the previous quarter and by 37% year-on-year
INCY's P/S is 35% below its 5-year quarterly average of 5.7 but 3.1% above its last 4 quarters average of 3.6
Incyte's revenue has increased by 10% YoY and by 2.4% from the previous quarter
Efficiency
How efficient is Incyte business performance
INCY's return on assets has dropped by 86% since the previous quarter and by 75% year-on-year
The ROE has plunged by 86% from the previous quarter and by 74% YoY
The ROIC has plunged by 67% from the previous quarter and by 50% YoY
INCY's ROS has shrunk by 66% QoQ and by 43% YoY
Dividends
What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INCY.
Financial health
How did Incyte financials performed over time
Incyte's total assets is 180% more than its total liabilities
The company's quick ratio has shrunk by 53% YoY and by 49% QoQ
The current ratio has contracted by 50% YoY and by 45% from the previous quarter
The debt is 99% smaller than the equity
INCY's equity is down by 44% since the previous quarter and by 37% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.